Physician profile
Lori A Call
NPI 1043681265
$2,142.34
in general payments reported to CMS, 2019-2025
16 companies · $1,026 in 2025
The $1,026 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $368 · 2023: $518 · 2024: $230 · 2025: $1,026.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,741 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,740.61 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $732.60 | 2022-2025 | Fasenra, Tezspire, Breztri |
| Amgen INC. | $424.19 | 2022-2025 | Tezspire |
| Genzyme Corporation | $228.00 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.85 | 2024-2025 | Ofev, Jascayd |
| Inari Medical, INC. | $112.87 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Glaxosmithkline, LLC. | $105.73 | 2022-2025 | Nucala |
| Grifols USA, LLC | $83.23 | 2022-2025 | Prolastin-C Liquid |
| Insmed, INC. | $74.00 | 2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $71.64 | 2024-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $46.20 | 2025 | Uptravi, Opsynvi, Opsumit |
| United Therapeutics Corporation | $30.67 | 2025 | Tyvaso |
| Takeda Pharmaceuticals U.S.A., INC. | $28.85 | 2025 | Glassia |
| Electromed, INC. | $27.30 | 2025 | Smartvest |
| Viatris Specialty LLC | $19.96 | 2025 | Yupelri |
| Philips North America LLC | $19.19 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $14.06 | 2023 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Call listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.